Compositions and method of manufacture for oral dissolvable dosage forms

A method of making a dissolvable drug-containing dosage-form for use in transmucosal delivery of a drug to a patient, the method comprising the steps of:

• a) selecting a binding agent that is dissolvable in the mouth of a patient;
• b) adding to the binding agent a pharmacologically effective dose of a potent central nervous system affecting drug, which can be absorbed through mucosal tissues of the mouth, pharynx, and esophagus of the patient;
• c) adding a buffer to the binding agent, the buffer capable of controlling the pH of the mouth, pharynx, and esophagus to optimize permeation of the drug in order to facilitate transmucosal absorption of the drug;
• d) mixing the binding agent, drug, and buffer into a moldable mixture in which the drug and enhancer are dispersed throughout the binding agent;
• and
• e) forming a solid matrix from the moldable mixture that is dissolvable in the mouth of the patient such that the drug is released for absorption through mucosal tissues of the mouth, pharynx, and esophagus of the patient.

A dissolvable drug-containing dosage form for use in transmucosal delivery of a drug to a patient, comprising:

• a) a binding agent that is formed into a solid matrix is dissolvable in the mouth of the patient;
• b) a potent dose of a central nervous system effecting drug that can be absorbed through mucosal tissues of the mouth, pharynx and esophagus, the drug disbursed throughout the solid matrix;
• and
• c) a buffer disbursed throughout the solid matrix, the buffer capable of controlling the pH of the mouth, pharynx and esophagus to optimized permeation of the drug in order to facilitate transmucosal absorption of the drug;
• wherein when the solid matrix dissolves in the mouth of the patient, the potent dose of the drug is controllably released for absorption through mucosal tissues of the mouth, pharynx and esophagus of the patient.

A dissolvable drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, comprising:

• a) a binding agent that is formed into a solid carbohydrate matrix dissolvable in the mouth of a patient,
• b) a pharmacologically effective dose of a potent central nervous system affecting drug that can be absorbed through mucosal tissues of the mouth, pharynx, and esophagus, the drug dispersed throughout the solid matrix;
• and
• c) a buffer dispersed throughout the solid matrix, the buffer capable of controlling the pH of the mouth, pharynx, and esophagus to optimize permeation of the drug in order to facilitate transmucosal absorption of the drug;
• wherein when the solid matrix dissolves in the mouth of the patient, the pharmacologically effective dose of the drug is released for absorption through mucosal tissues of the mouth, pharynx, and esophagus.

A dissolvable drug-containing dosage-form for use in the transmucosal delivery of a drug to a patient, comprising:

• a) a binding agent that is formed into a solid carbohydrate matrix dissolvable in the mouth of a patient, said carbohydrate being selected from the group of microcrystalline cellulose and carboxymethyl cellulose,
• b) a pharmacologically effective dose of a potent central nervous system affecting drug that can be absorbed through mucosal tissues of the mouth, pharynx, and esophagus, the drug dispersed throughout the solid matrix;
• and
• c) a buffer dispersed throughout the solid matrix, the buffer capable of controlling the pH of the mouth, pharynx, and esophagus to optimize permeation of the drug in order to facilitate transmucosal absorption of the drug;
• wherein when the solid matrix dissolves in the mouth of the patient, the pharmacologically effective dose of the drug is released for absorption through mucosal tissues of the mouth, pharynx, and esophagus.